



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

Guidelines for the Role of Lenalidomide in Multiple Myeloma (MM)

Approved Use:

Lenalidomide: In **combination with dexamethasone** in adult patients with progressive MM after at least one previous treatment, not resistant to dexamethasone, documented measurable disease and an ECOG performance status of 0 – 2.

- This policy recommendation represents a **new guideline document** and a restriction of lenalidomide to include patients with MM with progressive disease after at least one previous treatment.